ONWARD Reports Interim Clinical Outcomes for Implantable ARC Therapy Demonstrating Potential to Improve Blood Pressure Regulation after Spinal Cord Injury

Rentschler implements innovative learning program in collaboration with MassBioEd and WPI

Destiny Pharma: US FDA/CDC workshop highlights the need for new approaches for the prevention of hospital-acquired infections

Destiny Pharma announces finalisation of its Phase 3 development plans for XF-73 Nasal

Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study

Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies

Temedica raises another €25 million in Series B funding to expand its unique real-world insights ecosystem

HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor

Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

Marinomed Biotech AG reports increase in revenues for the first 9 months 2022 and significant business development progress